Teva, Pfizer settle on Viagra generic date

Share this article:

Teva announced yesterday afternoon that it had settled patent litigation with Pfizer and that the generics firm will be allowed to sell a copycat version of the blockbuster ED drug Viagra (sildenafil citrate) prior to the pill's official LOE date. Viagra's patent lapses in 2020, but this new settlement deal, terms of which the companies are keeping close to the vest, will allow the Israeli drug firm to roll out its copy by December 2017, Teva said, adding that it will pay a royalty to Pfizer for licensing. Its sildenafil ANDA has received tentative approval from the FDA. As of September 2013, Viagra had annual US sales of about $1.2 billion, according to IMS data cited by Teva.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters